Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA authority to remove products from market would be undermined by S 1035, agency testifies.

This article was originally published in The Gray Sheet

Executive Summary

FDA AUTHORITY TO REMOVE PRODUCTS FROM MARKET WOULD BE COMPROMISED by "The Access to Medical Treatment Act" (S 1035), FDA Executive Assistant to the Commissioner Jerold Mande asserted at a July 30 hearing on the bill before the Senate Labor and Human Resources Committee. The bill, sponsored by Minority Leader Tom Daschle (D-S.D.), would allow health practitioners to administer unapproved drugs, devices, foods or dietary supplements as long as there is no evidence that the treatment causes harm and the patient is informed about the treatment and its possible side effects.

You may also be interested in...



Pharma R&D’s COVID-19 Scar

Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.

Advancing The Precision Mission At RSNA 2020

RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.

Highest European Court Rules CBD Is Not A Narcotic Drug

The European Court of Justice rules that CBD cannot be regarded as a narcotic as it is non-psychoactive and suggests that a French ban on the cannabinoid is contrary to EU law on the free movement of goods. Legal experts and industry hope the judgment will pave the way for a regulated European CBD market.

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel